DexCom, Inc. (Nasdaq:DXCM) today reported a net loss of $11.3 million or $0.40 per share for the second quarter of 2007, compared to $11.2 million or $0.41 per share for the first quarter of 2006. The company reported revenues of $863,000 for the second quarter of 2007 compared to $479,000 for the second quarter of 2006 following the launch of its first product on March 28, 2006.
Cost of sales increased to $2.9 million for the second quarter of 2007 compared to $2.1 million for the second quarter in 2006. The increase was primarily related to a credit of $1.1 million in the 2006 period for materials purchased and expensed in 2005 while the company was in the development stage. Research and development expense decreased $1.3 million to $4.0 million for the second quarter of 2007, compared to $5.4 million for the second quarter of 2006. Changes in research and development expense include reduced clinical, regulatory, and development costs. Selling, general and administrative expense increased $538,000 to $5.5 million for the second quarter of 2007, compared to $4.9 million for the second quarter of 2006. The increase was primarily due to higher general and administrative and sales and marketing costs as the company continued to launch its STS and SEVEN systems in the United States.
Conference Call
Management will hold a conference call today starting at 4:30 pm (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (877) 704-5382 (US/Canada) or (913) 312-1296 (International) and use the participant code "6419342" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring systems for people with diabetes.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company’s products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company’s inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company’s development programs, the inability of patients to receive reimbursements from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ending June 30, 2007, as filed with the Securities and Exchange Commission on July 30, 2007.
DexCom, Inc. Balance Sheets (In thousands – except share and per share data) (Unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2007 | 2006 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,884 | $ | 18,167 | ||||
| Short-term marketable securities, available-for-sale | 58,316 | 36,341 | ||||||
| Accounts receivable, net | 126 | 120 | ||||||
| Inventory | 1,254 | 1,413 | ||||||
| Prepaid and other current assets | 1,939 | 1,315 | ||||||
| Total current assets | 87,519 | 57,356 | ||||||
| Property and equipment, net | 5,565 | 6,118 | ||||||
| Other assets | 3,443 | 1,079 | ||||||
| Total assets | $ | 96,527 | $ | 64,553 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 3,966 | $ | 2,764 | ||||
| Accrued payroll and related expenses | 2,106 | 1,558 | ||||||
| Current portion of long-term debt | 1,375 | 908 | ||||||
| Total current liabilities | 7,447 | 5,230 | ||||||
| Other long-term liabilities | 684 | 377 | ||||||
| Long-term debt, net of current portion | 61,719 | 2,118 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2007 and December 31, 2006, respectively. | — | — | ||||||
| Common stock, $0.001 par value, 100,000,000 authorized; 28,370,474 and 28,163,690 shares issued and outstanding at June 30, 2007 and December 31, 2006, respectively | 28 | 28 | ||||||
| Additional paid-in capital | 179,321 | 187,162 | ||||||
| Accumulated other comprehensive income (loss) | (33 | ) | 12 | |||||
| Accumulated deficit | (152,639 | ) | (130,374 | ) | ||||
| Total stockholders' equity | 26,677 | 56,828 | ||||||
| Total liabilities and stockholders' equity | $ | 96,527 | $ | 64,553 | ||||
DexCom, Inc. Statements of Operations (In thousands – except share and per share data) (Unaudited) | ||||||||||||||||
|
Three Months Ended
June 30, |
Six Months Ended
June 30, | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
| Revenues | $ | 863 | $ | 479 | $ | 1,875 | $ | 494 | ||||||||
| Cost of sales | 2,906 | 2,091 | 5,968 | 4,172 | ||||||||||||
| Gross margin | (2,043 | ) | (1,612 | ) | (4,093 | ) | (3,678 | ) | ||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 4,028 | 5,361 | 8,063 | 10,855 | ||||||||||||
| Selling, general and administrative | 5,469 | 4,931 | 10,840 | 8,773 | ||||||||||||
| Total operating expenses | 9,497 | 10,292 | 18,903 | 19,628 | ||||||||||||
| Operating loss | (11,540 | ) | (11,904 | ) | (22,996 | ) | (23,306 | ) | ||||||||
| Interest income (expense), net | 204 | 736 | 731 | 1,219 | ||||||||||||
| Net loss | $ | (11,336 | ) | $ | (11,168 | ) | $ | (22,265 | ) | $ | (22,087 | ) | ||||
| Basic and diluted net loss per share | $ | (0.40 | ) | $ | (0.41 | ) | $ | (0.79 | ) | $ | (0.84 | ) | ||||
| Shares used to compute basic and diluted net loss per share | 28,298,731 | 27,080,115 | 28,261,301 | 26,322,567 | ||||||||||||
Contacts:
Steven R. Pacelli
Senior Vice President of
Corporate Affairs
858-200-0200
www.dexcom.com
